CA Patent

CA2756222A1 — Transdermal delivery

Assigned to Agile Therapeutics Inc · Expires 2010-09-30 · 16y expired

What this patent protects

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

USPTO Abstract

Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval.

Drugs covered by this patent

Patent Metadata

Patent number: CA2756222A1
Jurisdiction: CA
Classification: —
Expires: 2010-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Agile Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.